Investigating the Feasibility of Targeted Next-Generation Sequencing to Guide the Treatment of Head and Neck Squamous Cell Carcinoma
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose Head and neck squamous cell carcinoma (HNSCC) is a deadly disease in which precision medicine needs to be incorporated. We aimed to implement next-generation sequencing (NGS) in determining actionable targets to guide appropriate molecular targeted therapy in HNSCC patients. Materials and Methods Ninety-three tumors and matched blood samples underwent targeted sequencing of 244 genes using the Illumina HiSeq 2500 platform with an average depth of coverage of greater than 1,000. Clinicopathological data from patients were obtained from 17 centers in Korea, and were analyzed in correlation with NGS data. Results Ninety-two of the 93 tumors were amenable to data analysis. TP53 was the most common mutation, occurring in 47 (51%) patients, followed by CDKN2A (n=23, 25%), CCND1 (n=22, 24%), and PIK3CA (n=19, 21%). The total mutational burden was similar between human papillomavirus (HPV)–negative vs. positive tumors, although TP53, CDKN2A and CCND1 gene alterations occurred more frequently in HPV-negative tumors. HPV-positive tumors were significantly associated with immune signature-related genes compared to HPV-negative tumors. Mutations of NOTCH1 (p=0.027), CDKN2A (p < 0.001), and TP53 (p=0.038) were significantly associated with poorer overall survival. FAT1 mutations were highly enriched in cisplatin responders, and potentially targetable alterations such as PIK3CA E545K and CDKN2A R58X were noted in 14 patients (15%). Conclusion We found several targetable genetic alterations, and our findings suggest that implementation of precision medicine in HNSCC is feasible. The predictive value of each targetable alteration should be assessed in a future umbrella trial using matched molecular targeted agents.
Abstract
Purpose Head and neck squamous cell carcinoma (HNSCC) is a deadly disease in which precision medicine needs to be incorporated. We aimed to implement next-generation sequencing (NGS) in determining actionable targets to guide appropriate molecular targeted therapy in HNSCC patients. Materials and Methods Ninety-three tumors and matched blood samples underwent targeted sequencing of 244 genes using the Illumina HiSeq 2500 platform with an average depth of coverage of greater than 1,000. Clinicopathological data from patients were obtained from 17 centers in Korea, and were analyzed in correlation with NGS data. Results Ninety-two of the 93 tumors were amenable to data analysis. TP53 was the most common mutation, occurring in 47 (51%) patients, followed by CDKN2A (n=23, 25%), CCND1 (n=22, 24%), and PIK3CA (n=19, 21%). The total mutational burden was similar between human papillomavirus (HPV)–negative vs. positive tumors, although TP53, CDKN2A and CCND1 gene alterations occurred more frequently in HPV-negative tumors. HPV-positive tumors were significantly associated with immune signature-related genes compared to HPV-negative tumors. Mutations of NOTCH1 (p=0.027), CDKN2A (p < 0.001), and TP53 (p=0.038) were significantly associated with poorer overall survival. FAT1 mutations were highly enriched in cisplatin responders, and potentially targetable alterations such as PIK3CA E545K and CDKN2A R58X were noted in 14 patients (15%). Conclusion We found several targetable genetic alterations, and our findings suggest that implementation of precision medicine in HNSCC is feasible. The predictive value of each targetable alteration should be assessed in a future umbrella trial using matched molecular targeted agents.
참고문헌 (32)
- Vermorken JB, "Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and", or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy, 2007, pp.25, 2171~2177
- Chow LQ, "Antitumor activity of pembrolizumab in biomarkerunselected patients with recurrent and", or metastatic head and neck squamous cell carcinoma : results from the phase Ib KEYNOTE-012 Expansion Cohort, 2016, pp.34, 3838~3845
- Agrawal N, "Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1", Science, 333, pp.1154~1157 (2011)
- Stransky N, "The mutational landscape of head and neck squamous cell carcinoma", Science, 333, pp.1157~1160 (2011)
- Cancer Genome Atlas Network, "Comprehensive genomic characterization of head and neck squamous cell carcinomas", Nature, 517, pp.576~582 (2015)
- Giefing M, "Moving towards personalised therapy in head and neck squamous cell carcinoma through analysis of next generation sequencing data", Eur J Cancer, 55, pp.147~157 (2016)
- "Sickle: a sliding-window, adaptive, quality-based trimming tool for FastQ files (version 1.33)" (2011)[URL]
- Li H, "Fast and accurate short read alignment with Burrows-Wheeler transform", Bioinformatics, 25, pp.1754~1760 (2009)
- McKenna A, "The Genome Analysis Toolkit : a MapReduce framework for analyzing next-generation DNA sequencing data", Genome Res, 20, pp.1297~1303 (2010)
- Cibulskis K, "Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples", Nat Biotechnol, 31, pp.213~219 (2013)
- Koboldt DC, "VarScan 2 : somatic mutation and copy number alteration discovery in cancer by exome sequencing", Genome Res, 22, pp.568~576 (2012)
- Costello M, "Discovery and characterization of artifactual mutations in deep coverage targeted capture sequencing data due to oxidative DNA damage during sample preparation", Nucleic Acids Res, 41, pp.e67~ (2013)
- Wang K, "ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data", Nucleic Acids Res, 38, pp.e164~ (2010)
- Griffith M, "CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer", Nat Genet, 49, pp.170~174 (2017)
- Ainscough BJ, "DoCM : a database of curated mutations in cancer", Nat Methods, 13, pp.806~807 (2016)
- Talevich E, "CNVkit: genomewide copy number detection and visualization from targeted DNA sequencing", PLoS Comput Biol, 12, pp.e1004873~ (2016)
- Waggott DM, "NanoString Norm: normalize NanoString miRNA and mRNA data", R Package, ~ (2015)
- Wang H, "NanoStringDiff: differential expression analysis of NanoString nCounter data", R Package, ~ (2015)
- Chau NG, "Incorporation of next-generation sequencing into routine clinical care to direct treatment of head and neck squamous cell carcinoma", Clin Cancer Res, 22, pp.2939~2949 (2016)
- Eisenhauer EA, "New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)", Eur J Cancer, 45, pp.228~247 (2009)
- Chung CH, "Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing", Ann Oncol, 26, pp.1216~1223 (2015)
- Seiwert TY, "Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas", Clin Cancer Res, 21, pp.632~641 (2015)
- Massard C, "High-throughput genomics and clinical outcome in hard-to-treat advanced cancers : results of the MOSCATO 01 trial", Cancer Discov, 7, pp.586~595 (2017)
- Mullard A, "NCI-MATCH trial pushes cancer umbrella trial paradigm", Nat Rev Drug Discov, 14, pp.513~515 (2015)
- Lui VW, "Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers", Cancer Discov, 3, pp.761~769 (2013)
- Tanoue T, "New insights into Fat cadherins", J Cell Sci, 118(Pt 11), pp.2347~2353 (2005)
- Morris LG, "Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation", Nat Genet, 45, pp.253~261 (2013)
- Kim KT, "Association between FAT1 mutation and overall survival in patients with human papillomavirusnegative head and neck squamous cell carcinoma", Head Neck, 38(Suppl 1), pp.E2021~E2029 (2016)
- Mandal R, "The head and neck cancer immune landscape and its immunotherapeutic implications", JCI Insight, 1, pp.e89829~ (2016)
- Mehra R, "Efficacy and safety of pembrolizumab in recurrent", metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012, 2018, pp.119, 153~159
- Gillison ML, "Nivolumab (nivo) vs. investigator's choice (IC)for recurrent or metastatic (R", M) head and neck squamous cell carcinoma (HNSCC): CheckMate-141, 2016, ~[DOI]
- Gusnanto A, "Correcting for cancer genome size and tumour cell content enables better estimation of copy number alterations from next-generation sequence data", Bioinformatics, 28, pp.40~47 (2012)